Natera Inc. (($NTRA)) has held its Q4 earnings call. Read on for the main highlights of the call. Natera Inc. Reports Strong Financial Performance ...

Welcome, everyone, to Natera's 2024 fourth-quarter financial results conference call. (Operator Instructions) As a reminder, this conference call is being recorded, today, February 27, 2025. I would, ...

Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Welcome everyone to Natera’s 2024 Fourth Quarter Financial ...

BTIG analyst Mark Massaro raised the firm’s price target on Natera (NTRA) to $190 from $185 and keeps a Buy rating on the shares. The company ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Natera (NTRA – Research Report), with a price target ...

Natera Inc (NTRA) reports a 53% revenue surge and outlines strategic initiatives amidst competitive pressures and ...

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsMike Brophy - Chief Financial ...

Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results beating Wall Street’s revenue expectations, with ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high- ...

The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.

In addition to the coverage in NSCLC, Signatera is also covered by Medicare for adjuvant and recurrence monitoring in colorectal cancer, muscle-invasive bladder cancer, breast cancer, and ovarian ...